8-K: Inozyme Pharma Announces Positive Topline Data for INZ-701 in Rare Disease Trials

Inozyme Pharma reports positive topline data from Phase 1/2 trials of INZ-701 in adults with ABCC6 and ENPP1 deficiencies, showing promising safety and efficacy results.

Summary

• Inozyme Pharma has released positive topline data from its Phase 1/2 clinical trials of INZ-701 for ABCC6 and ENPP1 deficiencies.
• The ABCC6 deficiency trial involved 10 adults across three dose cohorts, showing improvements in vascular pathology, retinal health, and visual function.
• Specifically, seven of eight evaluable patients showed reduction or stabilization of carotid intima-media thickness (cIMT), a marker for cardiovascular disease.
• Seven of eight evaluable patients also showed increased choroidal thickness, indicating a potential benefit for retinal disease.
• Four of six evaluable patients with low visual function scores improved over 48 weeks, with older patients showing greater improvement.
• All evaluable patients showed improvement on clinician-reported Global Impression of Change (C-GIC) scores, and seven of nine showed improvement on patient-reported scores (P-GIC).
• The ENPP1 deficiency trial included 13 adults across four dose cohorts, with significant reductions in fibroblast growth factor-23 (FGF-23) in the 1.8 mg/kg cohort.
• The 1.8 mg/kg cohort also showed increases in bone specific alkaline phosphatase and decreases in c-telopeptide, indicating improved bone mineralization.
• Patient-reported outcomes for pain, fatigue, and pain interference were favorable across all twice-weekly dose cohorts.
• Both trials showed favorable safety profiles with no serious or severe adverse events and low levels of non-neutralizing anti-drug antibodies.
• The company plans to initiate a pivotal trial in pediatric patients with ABCC6 Deficiency in the first quarter of 2025, subject to regulatory review and funding.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results with a clear path forward for regulatory approval and further development. The safety profile is favorable, and the company is addressing a significant unmet need. The only negative is the need for additional capital, but the overall tone is very optimistic.

Positives

• INZ-701 demonstrated a favorable safety profile in both trials, with no serious or severe adverse events.
• The drug showed positive effects on key disease markers in both ABCC6 and ENPP1 deficiency patients.
• There were improvements in patient-reported outcomes, including visual function and pain management.
• The immunogenicity profile was favorable, with low levels of non-neutralizing anti-drug antibodies.
• The company is planning a pivotal trial for pediatric ABCC6 deficiency patients, addressing a significant unmet need.
• The data supports the potential for once-weekly dosing of INZ-701 in ENPP1 deficiency patients.

Negatives

• The document does not explicitly mention any negative results from the trials.
• The document does mention that the company needs to raise substantial additional capital to achieve its business objectives.

Risks

• The company's ability to conduct ongoing and planned clinical trials is subject to risks.
• There are risks associated with obtaining and maintaining necessary approvals from regulatory authorities.
• The company needs to replicate positive results in later clinical trials.
• The company needs to manage expenses and comply with loan agreements.
• The company needs to raise substantial additional capital to achieve its business objectives.
• There is a risk that the company may not be able to advance the development of its product candidates under the timelines it anticipates.

Future Outlook

The company plans to work with the FDA and EMA on a pivotal trial design for pediatric ABCC6 deficiency and expects to initiate the trial in Q1 2025, subject to regulatory review and sufficient funding. The company also plans to continue development of INZ-701 for ENPP1 deficiency.

Management Comments

• Douglas A. Treco, Ph.D., CEO of Inozyme Pharma, stated that they are excited by the excellent safety and preliminary efficacy profile of INZ-701 in adults with ABCC6 Deficiency.
• Douglas A. Treco also mentioned that their investigations into the natural history of the disease have identified a substantial and previously overlooked pediatric population with a high risk of stroke.
• Professor Zulf Mughal, M.D., commented that he is very encouraged to see that INZ-701 may improve vascular pathology and believes that this effect may translate to clinical benefits in patients of all ages.

Industry Context

This announcement is significant in the rare disease space, as both ABCC6 and ENPP1 deficiencies have no approved therapies. The positive results for INZ-701 could position Inozyme as a leader in developing treatments for these conditions. The focus on pediatric patients with ABCC6 deficiency also highlights an unmet need in the market.

Comparison to Industry Standards

• The results are promising when compared to the current lack of approved therapies for ABCC6 and ENPP1 deficiencies.
• The observed improvements in cIMT and choroidal thickness in ABCC6 patients are notable, as these are key markers of disease progression.
• The reduction in FGF-23 and improvements in bone markers in ENPP1 patients are also significant, as these are direct indicators of the drug's mechanism of action.
• The favorable safety profile is consistent with the standards for enzyme replacement therapies, which are generally well-tolerated.
• The company's approach to targeting both adult and pediatric populations is aligned with the industry's focus on addressing unmet needs across all age groups.

Stakeholder Impact

• Shareholders are likely to react positively to the promising clinical trial results.
• Patients with ABCC6 and ENPP1 deficiencies and their families may have increased hope for effective treatments.
• Employees of Inozyme Pharma may be motivated by the positive progress of their work.
• Regulatory bodies will need to review the data for potential approvals.

Next Steps

• The company plans to work with the FDA and EMA on a pivotal trial design for pediatric ABCC6 deficiency.
• The company expects to initiate a pivotal trial in pediatric patients with ABCC6 Deficiency in the first quarter of 2025.
• The company will continue to develop INZ-701 for ENPP1 deficiency.

Key Dates

Keywords

INZ-701, ABCC6 Deficiency, ENPP1 Deficiency, Rare Disease, Clinical Trial, Phase 1/2, Vascular Pathology, Retinal Disease, Bone Mineralization, Enzyme Replacement Therapy, Pediatric Trial, Topline Data